CoChat

Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a low survival rate. Recently, new drugs that target KRASG12D, a common mutation in PDAC, have been developed. We studied one of these compounds, MRTX1133, and found it was specific and effective at low nanomolar concentrations in patient-derived organoid models and cell lines harboring KRASG12D mutations. Treatment with MRTX1133 upregulated the expression and phosphorylation of EGFR and HER2, indicating that inhibition of ERBB signaling may potentiate MRTX1133 antitumor activity. Indeed, the irreversible pan-ERBB inhibitor, afatinib, potently synergized with MRTX1133 in vitro, and cancer cells with acquired resistance to MRTX1133 in vitro remained sensitive to this combination therapy. Finally, the combination of MRTX1133 and afatinib led to tumor regression and longer survival in orthotopic PDAC mouse models. These results suggest that dual inhibition of ERBB and KRAS signaling may be synergistic and circumvent the rapid development of acquired resistance in patients with KRAS mutant pancreatic cancer. Significance: KRAS-mutant pancreatic cancer models, including KRAS inhibitor–resistant models, show exquisite sensitivity to combined pan-ERBB and KRAS targeting, which provides the rationale for testing this drug combination in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-23-1313

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Figure 1. MRTX1133 specifically targets oncogenic KRASG12D human and mouse PDAC models and leads to the upregulation of ERBB activation. A, Dose–response analysis of PDOs harboring the KRASWT, KRASG12V, or KRASG12D alleles 5 days after treatment with MRTX1133. B, Immunoblot analyses of the upstream and downstream targets of KRAS signaling in hT102 (KRASWT) and hM1F (KRASG12D) at 0, 3, 24, and 72 hours using 60 nmol/L MRTX1133. C, Quantification of B. D, Dose–response analysis of PDAC cell lines harboring the KRASWT or KRASG12D alleles 3 days after treatment with MRTX1133. E, Immunoblot analyses of the upstream and downstream targets of KRAS in BXPC3 (KRASWT) and SUIT2 (KRASG12D) at 0, 3, 24, and 72 hours using 60 nmol/L MRTX1133 for BXPC3 and SUIT2. F, Quantification of E. G, Dose–response analysis of mouse KRASG12D KPC organoids 3 days after treatment with MRTX1133. H, Immunoblot analyses of the upstream and downstream targets of KRAS in two different KPC mouse organoids (mT3 and mT9) at 0, 3, 24, and 72 hours using 60 nmol/L MRTX1133. I, Quantification of H. J, Dose–response analysis of mouse KRASG12D KPC cell lines 3 days after treatment with MRTX1133. K, Immunoblot analyses of the upstream and downstream targets of KRAS in two different KPC lines at 0, 3, 24, and 72, hours using 60 nmol/L MRTX1133. L, Quantification of K. Data, mean values ± SD. Immunoblots are representative of at least three independent experiments.
Figure 1. MRTX1133 specifically targets oncogenic KRASG12D human and mouse PDAC models and leads to the upregulation of ERBB activation. A, Dose–response analysis of PDOs harboring the KRASWT, KRASG12V, or KRASG12D alleles 5 days after treatment with MRTX1133. B, Immunoblot analyses of the upstream and downstream targets of KRAS signaling in hT102 (KRASWT) and hM1F (KRASG12D) at 0, 3, 24, and 72 hours using 60 nmol/L MRTX1133. C, Quantification of B. D, Dose–response analysis of PDAC cell lines harboring the KRASWT or KRASG12D alleles 3 days after treatment with MRTX1133. E, Immunoblot analyses of the upstream and downstream targets of KRAS in BXPC3 (KRASWT) and SUIT2 (KRASG12D) at 0, 3, 24, and 72 hours using 60 nmol/L MRTX1133 for BXPC3 and SUIT2. F, Quantification of E. G, Dose–response analysis of mouse KRASG12D KPC organoids 3 days after treatment with MRTX1133. H, Immunoblot analyses of the upstream and downstream targets of KRAS in two different KPC mouse organoids (mT3 and mT9) at 0, 3, 24, and 72 hours using 60 nmol/L MRTX1133. I, Quantification of H. J, Dose–response analysis of mouse KRASG12D KPC cell lines 3 days after treatment with MRTX1133. K, Immunoblot analyses of the upstream and downstream targets of KRAS in two different KPC lines at 0, 3, 24, and 72, hours using 60 nmol/L MRTX1133. L, Quantification of K. Data, mean values ± SD. Immunoblots are representative of at least three independent experiments.CC BY-NC-ND · PubMed Central
Figure 2. Irreversible Pan-ERBB inhibitors work synergistically with MRTX1133 in vitro. A, Evaluation of the synergistic effect of MRTX1133 with afatinib (panERBB inhibitor), lapatinib (EGFR/HER2 inhibitor), erlotinib (EGFR inhibitor), trametinib (MEK1/2 inhibitor), and ulixertinib (ERK1/2 inhibitor) using the BLISS synergy model in hF44 PDO, B and C, SUIT2 (B), and ASPC1 (C) show the potent and consistent synergy of MRTX1133 with afatinib. D–F, Western blot analyses of the upstream and downstream pathway targets of KRAS show a synergistic downregulation of the expression of EGFR and HER2 in hM1F (D), SUIT2 (E), and ASPC1 (F). G–I, Quantification of D, E, and F, respectively. Data, mean values ± SD. Immunoblots are representative of at least three independent experiments.
Figure 2. Irreversible Pan-ERBB inhibitors work synergistically with MRTX1133 in vitro. A, Evaluation of the synergistic effect of MRTX1133 with afatinib (panERBB inhibitor), lapatinib (EGFR/HER2 inhibitor), erlotinib (EGFR inhibitor), trametinib (MEK1/2 inhibitor), and ulixertinib (ERK1/2 inhibitor) using the BLISS synergy model in hF44 PDO, B and C, SUIT2 (B), and ASPC1 (C) show the potent and consistent synergy of MRTX1133 with afatinib. D–F, Western blot analyses of the upstream and downstream pathway targets of KRAS show a synergistic downregulation of the expression of EGFR and HER2 in hM1F (D), SUIT2 (E), and ASPC1 (F). G–I, Quantification of D, E, and F, respectively. Data, mean values ± SD. Immunoblots are representative of at least three independent experiments.CC BY-NC-ND · PubMed Central
Figure 3. MRTX1133 and afatinib combination remains effective in cells that have acquired MRTX1133 resistance. A and B, Cell viability of parental and MRTXR SUIT2 lines after treatment with MRTX1133 (A) or afatinib (B). C, Evaluation of the synergistic effect of MRTX1133 with afatinib using the BLISS and HSA synergy models in MRTXR SUIT2. D and E, Immunoblot analysis for the upstream and downstream signaling of KRAS after single-agent (D) or combination therapy with MRTX1133 and afatinib (E). F, qRT-PCR analysis KRAS expression in parental and MRTXR SUIT2 cells. G, Immunoblot analysis for RASG12D in parental or MRTXR SUIT2. H, Immunoblot analysis of RASG12D and pan-RAS in parental SUIT2, untreated MRTXR SUIT2, and MRTX1133-treated MRTXR SUIT2 after RAS-GTP pulldown. I, Quantification of H. Values are quantifications from two different Western blots normalized to 0.6% GAPDH input. Data, mean values ± SD. Immunoblots are representative of at least three independent experiments.
Figure 3. MRTX1133 and afatinib combination remains effective in cells that have acquired MRTX1133 resistance. A and B, Cell viability of parental and MRTXR SUIT2 lines after treatment with MRTX1133 (A) or afatinib (B). C, Evaluation of the synergistic effect of MRTX1133 with afatinib using the BLISS and HSA synergy models in MRTXR SUIT2. D and E, Immunoblot analysis for the upstream and downstream signaling of KRAS after single-agent (D) or combination therapy with MRTX1133 and afatinib (E). F, qRT-PCR analysis KRAS expression in parental and MRTXR SUIT2 cells. G, Immunoblot analysis for RASG12D in parental or MRTXR SUIT2. H, Immunoblot analysis of RASG12D and pan-RAS in parental SUIT2, untreated MRTXR SUIT2, and MRTX1133-treated MRTXR SUIT2 after RAS-GTP pulldown. I, Quantification of H. Values are quantifications from two different Western blots normalized to 0.6% GAPDH input. Data, mean values ± SD. Immunoblots are representative of at least three independent experiments.CC BY-NC-ND · PubMed Central
Figure 4. Irreversible Pan-ERBB inhibitor, afatinib, potentiates MRTX1133 in vivo. A, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. B, Tumor weights of mice in A. C, Tumors of mice in A imaged at necropsy. D, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with MRTXR SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. E, Tumor weights of mice in D. F, Tumors of mice in D imaged at necropsy. G, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. H, Tumor weights of mice in G. I, Tumors of mice in G imaged at necropsy. J, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with MRTXR KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. K, Tumor weights of mice in J. L, Tumors of mice in J imaged at necropsy. M, Survival study of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated with vehicle, MRTX1133, afatinib, or combo. †, censored data; *, P < 0.05; **, P < 0.01; ***, P < 0.001, log-rank test. Data, mean values ± SD.
Figure 4. Irreversible Pan-ERBB inhibitor, afatinib, potentiates MRTX1133 in vivo. A, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. B, Tumor weights of mice in A. C, Tumors of mice in A imaged at necropsy. D, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with MRTXR SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. E, Tumor weights of mice in D. F, Tumors of mice in D imaged at necropsy. G, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. H, Tumor weights of mice in G. I, Tumors of mice in G imaged at necropsy. J, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with MRTXR KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. K, Tumor weights of mice in J. L, Tumors of mice in J imaged at necropsy. M, Survival study of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated with vehicle, MRTX1133, afatinib, or combo. †, censored data; *, P < 0.05; **, P < 0.01; ***, P < 0.001, log-rank test. Data, mean values ± SD.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 89

Metadata

Authors
Gulay, K. C. M., Zhang, X., Pantazopoulou, V., Patel, J., Esparza, E., Pran Babu, D. S., Ogawa, S., Weitz, J., Ng, I., Mose, E. S., Pu, M., Engle, D. D., Lowy, A. M., & Tiriac, H.
Affiliations
  • University of California San Diego (US)
  • Salk Institute for Biological Studies (US)
  • 1Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, California.
Corresponding author
Tiriac, Hervé
Venue
Cancer Research
Published
2023-06-28
Volume
83
Issue
18
Pages
3001-3012
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4382344153
Cited by
89
References
29
Citations by year
2026: 28 · 2025: 35 · 2024: 22 · 2023: 4
FWCI
10.81
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • Lustgarten Foundation
  • Alexandrina M. McAfee Trust Foundation
  • Research for a Cure of Pancreatic Cancer Fund
  • Kakenhi (JP21J01035)
  • Swedish Research Council
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic ductal adenocarcinoma, KRAS G12D mutation, MRTX1133, afatinib, EGFR, HER2, combination therapy, drug synergy, acquired drug resistance, patient-derived organoids, orthotopic mouse model
MeSH terms
Afatinib, Animals, Heterocyclic Compounds, 2-Ring, Mutation, Naphthalenes, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-23-1313
The paper
Gulay, K. C. M., Zhang, X., Pantazopoulou, V., Patel, J., Esparza, E., Pran Babu, D. S., Ogawa, S., Weitz, J., Ng, I., Mose, E. S., Pu, M., Engle, D. D., Lowy, A. M., & Tiriac, H. (2023). Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-23-1313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.